ANTX Latest Press Releases

-- June 4, 2026 --

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease Business Wire 7:00 AM

-- May 21, 2026 --

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference Business Wire 7:00 AM

-- May 11, 2026 --

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights Business Wire 4:01 PM

-- May 7, 2026 --

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum Business Wire 4:01 PM

-- March 31, 2026 --

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease Business Wire 7:00 AM

-- March 17, 2026 --

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights Business Wire 4:00 PM

-- March 9, 2026 --

AN2 Therapeutics Announces $40 Million Private Placement Financing Business Wire 7:00 AM

-- March 3, 2026 --

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) Business Wire 4:00 PM

-- February 17, 2026 --

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference Business Wire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software